GRI vs HALO

GRI Bio, Inc. vs Halozyme Therapeutics, Inc. — Valuation Comparison 2026

By CirclFi Research Team · Updated 2026-06-03 · Data from SEC EDGAR, FRED & GDELT

Quick Summary — HALO scores higher on quality with 10.0/10 vs GRI's 3.9/10. GRI trades at $2.01 while HALO trades at $66.28. Both analyzed daily using SEC EDGAR data across 13 institutional models.

GRI

Biotechnology
GRI Bio, Inc.
Quality
3.9
out of 10
Value Trap
15
SAFE
Price
$2.01
Last close
Models
6/13
Active
VS

HALO

Biotechnology
Halozyme Therapeutics, Inc.
Quality
10.0
out of 10
Value Trap
25
LOW
Price
$66.28
Last close
Models
12/13
Active
GRI
Bayesian DCF sees +95.6% upside
Quality 3.9/10 — below average
HALO
Bayesian DCF sees +11.0% upside
Limited to 2/13 visible models

GRI vs HALO — Fair Value Comparison

GRI
$0$2$3$5 Price$2.01 Bayesian …$3.93 (+95.6%) ML-RIV$0.05 (-97.9%)
HALO
$0$29$58$87 Price$66.28 Bayesian …$73.55 (+11.0%) Earnings …$22.51 (-66.0%)
Market Price Model 1 Model 2

Model-by-Model Comparison

ModelType GRI Fair ValueGRI Upside HALO Fair ValueHALO Upside
Bayesian DCF Intrinsic $3.93 +95.6% $73.55 +11.0%
Earnings Power Value Intrinsic $22.51 -66.0%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.05 -97.9% $7.80 -88.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%

GRI vs HALO — Which Stock Is More Undervalued in 2026?

HALO scores higher with a 10.0/10 quality rating vs GRI's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do GRI and HALO Valuations Compare?

At $2.01, GRI trades +95.6% below its Bayesian DCF fair value of $3.93, while HALO at $66.28 trades +11.0% below its estimate of $73.55. GRI shows a wider gap between price and intrinsic value.

Quality of Company: GRI vs HALO

GRI earns a Quality of Company score of 3.9/10 compared to HALO's 10.0/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: GRI vs HALO

GRI carries a SAFE value trap risk (15/100) while HALO shows LOW risk (25/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Biotechnology

Both GRI and HALO operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare GRI vs HALO differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo  ·  FactSet: ~$1,000/mo  ·  CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

See all Biotechnology stocks →